Epidemiology of clinical isolates of Candida albicans and their susceptibility to triazoles

International Journal of Antimicrobial Agents

Volumn 20, Issue 6, 2002, Pages 472-475

  Wroblewska, M M ^a,b   Swoboda Kopec, E ^a,b   Rokosz, A ^a   Krawczyk, E ^a   Marchel, H ^b   Luczak, M ^a,b  

^a MEDICAL UNIVERSITY OF WARSAW   (Poland)

^b Central Clinical Hospital in Warsaw   (Poland)

Author keywords

Candida albicans; Nosocomial infections; Triazoles

Indexed keywords

FLUCONAZOLE; ITRACONAZOLE; TRIAZOLE DERIVATIVE; ANTIFUNGAL AGENT;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ARTICLE; CANDIDA ALBICANS; CONTROLLED STUDY; FUNGAL STRAIN; FUNGUS CULTURE; FUNGUS ISOLATION; HOSPITAL DEPARTMENT; HOSPITALIZATION; NONHUMAN; PRIORITY JOURNAL; CANDIDIASIS; CROSS INFECTION; DRUG EFFECT; HUMAN; MICROBIOLOGY; RETROSPECTIVE STUDY;

ANTIFUNGAL AGENTS; CANDIDA ALBICANS; CANDIDIASIS; CROSS INFECTION; DRUG RESISTANCE, FUNGAL; FLUCONAZOLE; HUMANS; ITRACONAZOLE; RETROSPECTIVE STUDIES;

EID: 0036891492     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0924-8579(02)00246-7     Document Type: Article

References (28)

1. Abi-Said D., Anaissie E., Uzun O., Raad I., Pinzcowiski H., Vartivarian S. The epidemiology of hematogenous candidiasis caused by different Candida species. Clin. Infect. Dis. 24:1997;1122-1128.
2. Cutler J.E. Putative virulence factors of Candida albicans. Ann. Rev. Microbiol. 45:1991;187-218.
3. Mitchell T.G. Medical mycology. Brooks G.F., Butel J.S., Morse S.A. Jawetz, Melnick and Adelberg's medical microbiology. 2001;Lange Medical Books/McGraw-Hill, New York.
4. Smith L.A., Fothergill A.W., Sutton D.A., Harris J.L. Medically significant fungi. Mahon C.R., Manuselis G. Textbook of diagnostic microbiology. 2000;W.B. Saunders Company, Philadelphia.
5. Warren N.G., Hazen K.C. Candida, Cryptococcus and other yeasts of medical importance. Murray P.R., Baron E.J., Pfaller M.A., Tenover F.C., Yolken R.H. Manual of clinical microbiology. 1999;ASM Press, Washington, DC.
6. Arndt C.A.S., Walsh T.J., McCully C.L., Balis F.M., Pizzo P.A., Poplack D.G. Fluconazole penetration into cerebrospinal fluid: implications for treating fungal infections of the central nervous system. J. Infect. Dis. 157:1998;178-180.
7. Kauffman C.A. Role of azoles in antifungal therapy. Clin. Infect. Dis. 22:(Suppl 2):1996;S148-S153.
8. Espinel-Ingroff A., White T., Pfaller M.A. Antifungal agents and susceptibility testing. Murray P.R., Baron E.J., Pfaller M.A., Tenover F.C., Yolken R.H. Manual of clinical microbiology. 1999;ASM Press, Washington, DC.
9. Espinel-Ingroff A., Rodriguez-Tudela J.L., Martinez-Suarez J.V. Comparison of two alternative microdilution procedures with the National Committee for Clinical Laboratory Standards reference macrodilution method M27-P for in vitro testing of fluconazole-resistant and -susceptible isolates of Candida albicans. J. Clin. Microbiol. 33:1995;3154-3158.
10. Willinger B., Apfalter P., Hirschl A.M., Makristathis A., Rotter M., Seibold M. Susceptibility testing of Candida species: comparison of NCCLS microdilution method with Fungitest. Diagn. Microbiol. Infect. Dis. 1:2000;11-15.
11. Swinne D., Raes-Wuytack C., Van Looveren K., Desmet P. Comparative evaluation of Fungitest, Neo-Sensitabs and M27T-NCCLS broth microdilution methods for antifungal drug susceptibility testing of Candida species and Cryptococcus neoformans. Mycoses. 42:1999;231-237.
12. Baumgartner C., Freydiere A., Gile Y. Direct identification and recognition of yeast species from clinical material by using Albicans ID and CHROMagar Candida plates. J. Clin. Microbiol. 34:1996;454-456.
13. Fricker-Hidalgo H., Vandapel O., Duchesne M.A., et al. Comparison of the new API Candida system to the ID 32 C system for the identification of clinically important yeast species. J. Clin. Microbiol. 34:1996;1846-1848.
14. Pfaller M.A., Houston A., Coffman S. Application of CHROMagar Candida for rapid screening of clinical specimens for Candida albicans, Candida tropicalis, Candida krusei and Candida (Torulopsis) glabrata. J. Clin. Microbiol. 34:1996;58-61.
15. NCCLS. Antifungal Susceptibility Testing; Committee Report. NCCLS document M27-T. NCCLS, Villanova, PA; 1995.
16. St-Germain G., Laverdiere M., Pelletier R., et al. Prevalence and antifungal susceptibility of 442 Candida isolates from blood and other normally sterile sites: results of a 2-year (1996 to 1998) multicenter surveillance study in Quebec, Canada. J. Clin. Microbiol. 39:2001;949-953.
17. Safdar A., Chaturvedi V., Cross E.W., et al. Prospective study of Candida species in patients at a comprehensive cancer center. Antimicrob. Agents Chemother. 45:2001;2129-2133.
18. Rex J.H., Rinaldi M.G., Pfaller M.A. Resistance of Candida species to f1uconazole. Antimicrob. Agents Chemother. 39:1995;1-8.
19. Magaldi S., Mata S., Hartung C., et al. In vitro susceptibility of 137 Candida sp. isolates from HIV patients to several antifungal agents. Mycopathologia. 149:2001;63-68.
20. White T.C. Antifungal drug resistance in Candida albicans. ASM News. 63:1997;427-433.
21. White T.C., Bowden R.A., Marr K.A. Clinical, cellular and molecular factors that contribute to antifungal drug resistance. Clin. Microbiol. Rev. 11:1998;382-402.
22. Perea S., Lopez-Ribot J.L., Kirkpatrick W.R., et al. Prevalence of molecular mechanisms of resistance to azole antifungal agents in Candida albicans strains displaying high-level fluconazole resistance isolated from human immunodeficiency virus-infected patients. Antimicrob. Agents Chemother. 45:2001;2676-2684.
23. Pfaller M.A., Jones R.N., Messer S.A., Edmond M.B., Wenzel R.P. National surveillance of nosocomial blood stream infection due to Candida albicans: frequency of occurrence and antifungal susceptibility in the SCOPE program. Diagn. Microbiol. Infect. Dis. 31:1998;327-332.
24. Liebowitz L.D., Ashbee H.R., Evans E.G. A two year global evaluation of the susceptibility of Candida species to fluconazole by disk diffusion. Diagn. Microbiol. Infect. Dis. 40:2001;27-33.
25. Goldman M., Cloud G.A., Smedema M., et al. Does long-term itraconazole prophylaxis result in in vitro azole resistance in mucosal Candida albicans isolates from persons with advanced human immunodeficiency virus infection? The National Institute of Allergy and Infectious Diseases Mycoses Study group. Antimicrob. Agents Chemother. 44:2000;1585-1587.
26. Lopez J., Pernot C., Aho S., et al. Decrease in Candida albicans strains with reduced susceptibility to fluconazole following changes in prescribing policies. J. Hosp. Infect. 48:2001;122-128.
27. Johnson E.M., Davey K.G., Szekely A., Warnock D.W. Itraconazole susceptibilities of fluconazole susceptible and resistant isolates of five Candida species. J. Antimicrob. Chemother. 36:1995;787-793.
28. Branchini M.L., Aoki F.H., Colombo A.L., Taguchi H., Yamamoto K., Miyazi M. Effect of antifungal agents on Candida spp. and Pichia anomala isolated from oropharyngeal candidiasis of AIDS patients in a university hospital in Brazil. Braz. J. Infect. Dis. 2:1998;187-196.